Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Natural cytotoxicity triggering receptor 2 ligands” refers collectively to the **ligands** that bind to **natural cytotoxicity triggering receptor 2 (NCR2 / NKp44)**, an activating receptor expressed mainly on human natural killer (NK) cells.[6][7][5] NCR2 itself is a type I transmembrane receptor with an extracellular Ig-like domain that associates with adaptor molecules to transduce activating signals, but “NCR2 ligands” is not a single, well-defined molecular entity; instead, multiple, structurally unrelated ligands on target cells (such as tumor cells, virus‑infected cells, or stressed cells, including a ligand described on astrocytes) can engage NKp44 and modulate NK cell cytotoxicity and cytokine production.[3][5][6] Because the query groups all ligands together rather than specifying one molecular species, it is not a properly canonical single target name and should be treated as an imprecise/aggregate term rather than a unique drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural cytotoxicity triggering receptor 2 ligands.